Conde-Sala, J. L., Reñé-Ramírez, R., Turró-Garriga, O., Gascón-Bayarri, J., Juncadella-Puig, M., Moreno-Cordón, L., Viñas-Diez, V., & Garre-Olmo, J. (2013). Clinical differences in patients with Alzheimer’s disease according to the presence or absence of anosognosia: Implications for perceived quality of life. Journal of Alzheimer’s Disease, 33(4), 1105–1116. https://doi.org/10.3233/JAD-2012-121360Gerretsen, P., Chung, J. K., Shah, P., Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Pollock, B. G., Graff-Guerrero, A., & Alzheimer’s Disease Neuroimaging Initiative. (2017). Anosognosia is an independent predictor of conversion from mild cognitive impairment to Alzheimer’s disease and is associated with reduced brain metabolism. Journal of Clinical Psychiatry, 78(9), e1187–e1193. https://doi.org/10.4088/JCP.17m11545
Hallam, B., Chan, J., Gonzalez Costafreda, S., Bhome, R., & Huntley, J. (2020). What are the neural correlates of meta-cognition and anosognosia in Alzheimer’s disease? A systematic review. Neurobiology of Aging, 94, 250–264. https://doi.org/10.1016/j.neurobiolaging.2020.06.011
Jordán de Urríes Bonal, P., Ramos Campos, F., & Jordán de Urríes Vega, F. de B. (2026). Anosognosia en la enfermedad de Alzheimer y el deterioro cognitivo leve: Una revisión sistemática. Revista Iberoamericana de Neuropsicología, 9(1), 35–50.
Latgé-Tovar, C. F., Berrios-Morales, P., Smith, J. A., Wang, J., Satler, A., Gagnon, L., Mares, M. A., & Werner, P. (2024). The use of virtual reality as a perspective-taking manipulation to improve self-awareness in Alzheimer’s disease. Frontiers in Aging Neuroscience, 16, 1376413. https://doi.org/10.3389/fnagi.2024.1376413
Mondragón, J. D., Maurits, N. M., & De Deyn, P. P. (2019). Functional neural correlates of anosognosia in mild cognitive impairment and Alzheimer’s disease: A systematic review. Neuropsychology Review, 29(2), 139–165. https://doi.org/10.1007/s11065-019-09410-x
Prigatano, G. P., Russell, B., & Meites, K. (2024). Studying lack of awareness of cognitive decline in neurodegenerative diseases requires measures of both anosognosia and denial. Frontiers in Aging Neuroscience, 15, 1325231. https://doi.org/10.3389/fnagi.2023.1325231
Turró-Garriga, O., Garre-Olmo, J., López-Pousa, S., Vilalta-Franch, J., Reñé-Ramírez, R., & Conde-Sala, J.-L. (2014). Abridged scale for the screening anosognosia in patients with dementia. Journal of Geriatric Psychiatry and Neurology, 27(3), 220–226. https://doi.org/10.1177/0891988714527515
Turró-Garriga, O., Garre-Olmo, J., Reñé-Ramírez, R., Calvó-Perxas, L., Gascón-Bayarri, J., & Conde-Sala, J.-L. (2016). Consequences of anosognosia on the cost of caregivers’ care in Alzheimer’s disease. Journal of Alzheimer’s Disease, 54(4), 1551–1560. https://doi.org/10.3233/JAD-160419
Wang, S., Mimmack, K., Cacciamani, F., Elnemais Fawzy, M., Munro, C., Gatchel, J., Marshall, G. A., Gagliardi, G., & Vannini, P. (2024). Anosognosia is associated with increased prevalence and faster development of neuropsychiatric symptoms in mild cognitive impairment. Frontiers in Aging Neuroscience, 16, 1335878. https://doi.org/10.3389/fnagi.2024.1335878